Preparing for human papillomavirus vaccine introduction in Kenya: Implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Friedman, Allison L ^a   Oruko, Kelvin O ^a   Habel, Melissa A ^a   Ford, Jessie ^b   Kinsey, Jennine ^a   Odhiambo, Frank ^a   Phillips Howard, Penelope A ^c   Wang, Susan A ^d   Collins, Tabu ^e   Laserson, Kayla F ^a   Dunne, Eileen F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e MINISTRY OF HEALTH   (Kenya)

Author keywords

Communication; HPV vaccine acceptability; Kenya; Low or middle income countries; Mobilization; Qualitative research

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; CAREGIVER; CHILD; FEMALE; HEALTH PROMOTION; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; KENYA; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PARENT; PATIENT ATTITUDE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

ADOLESCENT; ADULT; CAREGIVERS; CHILD; COMMUNICATION; FEMALE; FOCUS GROUPS; HEALTH PROMOTION; HUMANS; KENYA; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PARENTS; PATIENT ACCEPTANCE OF HEALTH CARE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84938500925     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-855     Document Type: Review

References (43)

1. International Agency for Research on Cancer: GLOBOCAN Cancer Fact Sheet: Cervical Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. [http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp]
2. World Health Organization (WHO)/International Agency for Research on Cancer: The Global Cancer Atlas: Africa. [http://globocan.iarc.fr/ia/Africa/atlas.html]
3. Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Albero G, Cosano R, Muñoz J, Bosch FX, de Sanjosé S, Castellsagué X, ICO Information Centre on HPV and Cancer (HPV Information Centre): Human Papillomavirus and Related Diseases in Kenya. Summary Report 2014-08-22. [http://www. hpvcentre.net/statistics/reports/KEN.pdf]
4. Ministry of Public Health and Sanitation and Ministry of Medical Services: National cervical cancer prevention program strategic plan 2012-2015. [http://www.iedea-ea.org/joomla/attachments/article/304/National% 20Cervical%20Cancer%20Prevention%20Plan%20FINALFeb%202012.pdf]
5. U.S. Centers for Disease Control and Prevention (CDC): HPV Vaccine Safety. [http://www.cdc.gov/vaccinesafety/Vaccines/HPV/Index.html]
6. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA for the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl JMed 2007, 356:1928-1943.
7. The FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
8. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G for the HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
9. WHO: Human papillomavirus vaccines: WHO position paper. WHO Weekly Epidemiol Record 2009, 84:118.
10. WHO: Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation. [http://whqlibdoc.who.int/hq/2005/WHO-IVB-05.18.pdf]
11. GAVI: GAVI opens 2012 applications for new vaccines support + HPV demos. [http://www.who.int/pmnch/media/news/2012/gavi-vaccine- applications/en/]
12. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F: Chapter 15: HPV vaccine use in the developing world. Vaccine 2006, S3:132-139.
13. WHO: Preparation for the Introduction of HPV Vaccine:Policy and Program Guidance for Countries. Geneva, Switzerland: WHO Press, World Health Organization; 2006.
14. WHO: Department of Immunization, Vaccine and Biologicals, Expanded Programme on Immunization. Geneva, Switzerland: Report of the HPV Vaccine Delivery Meeting: Identifying Needs for Implementation & Research; 2012.
15. Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M: Chapter 25: Education, training, and communication for HPV vaccines. Vaccine 2006, 24(S3):210-218.
16. PATH: Conducting Formative Research for HPV Vaccination Program Planning. Seattle: Practical Experience from PATH; 2012.
17. Vermandere H, Degomme O, Temmerman M, Chersich M, Vanden Broeck D: Cervical cancer prevention in Eldoret, Kenya: Assessing acceptability and intention-to participate in an HPV vaccination program [abstract]. The 28th International Papillomavirus Conference Proceedings; 2012. http://www. hpv2012pr.org/HPV2012-PUERTO-RICO-Program-Book.PDF]
18. Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS: HPV vaccine acceptability among Kenyan women. Vaccine 2010, 28:4864-4867.
19. PATH, Child Health and Development Centre (CHDC), and the Uganda National Expanded Program on Immunization (UNEPI): HPV Vaccination in Africa: Lessons Learned from a Pilot Program in Uganda. Seattle: 2011 [www.path.org/publications/files/RH-hpv-lessons-learned-uganda.pdf]
20. Bingham A, Drake JK, LaMontagne DS: Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009, 163:455-461.
21. CARE Kenya: Community initiatives for Child Survival Siaya (CICSS-II): Detailed Implementation Plan 2000. [http://pdf.usaid.gov/pdf-docs/ PDABS211.pdf]
22. University of New Mexico School of Medicine: Research and Clinical Facilities in Siaya, Kenya. [http://medicine.unm.edu/globalhealth/facilities/ siaya.html]
23. National AIDS Control Council (NACC) and National AIDS and STI Control Programme (NASCOP): Kenya AIDS Epidemic update. 2011, www.unaids. org/en/dataanalysis/knowyourresponse/countryprogressreports/ 2012countries/ce-KE-Narrative-Report.pdf]
24. Pavin M, Odingo G, Jeon C, Frajzyngier V, Perchal P: Assessing Two Strategies for Expanding Coverage of Adult Male Circumcision in Nyanza Province, Kenya. New York: EngenderHealth; 2011.
25. Harry B, Sturges K, Klinger J: Mapping the process: An exemplar of process and challenge in grounded theory analysis. Educ Res 2005, 34:3-13.
26. DeCuir-Gunby JT, Marshall PL, McCulloch AW: Developing and using a codebook for the analysis of interview data: An example from a professional development research project. Field Methods 2011, 23:136-155.
27. Katahoire RA, Jitta J, Kivumbi G, Murokora D, Arube WJ, Siu G, Arinaitwe L, Bingham A, Mugisha E, Tsu V, LaMontagne DS: An assessment of the readiness for introduction of the HPV vaccine in Uganda. Afr J Reprod Health 2008, 12:159-172.
28. Harries J, Moodley J, Barone MA, Mall S, Sinanovic E: Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009, 27:38-44.
29. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F: Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Org 2012, 90:623-628.
30. Galagan SR, Paul P, Menezes L, Lamontagne DS: Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine 2013, 31:3072-3078.
31. LIVESTRONG: Cancer Stigma and Silence around the World: A LIVESTRONG Report. [http://livestrong.org/pdfs/3-0/LSGlobalResearchReport]
32. Department for International Development (DFID): Taking Action Against HIV Stigma and Discrimination: Guidance Document and Supporting Resources. [http://www.icrw.org/files/publications/DFID-Taking-Action-Against-HIV-Stigma-and-Discrimination.pdf]
33. Piotrow PT, Kincaid DL, Rimon JG, Rinehart W: Health Communication Lessons from Family Planning and Reproductive Health. Westport: Praeger; 1997.
34. Watson-Jones D, Tomlin K, Remes P, Baisley K, Ponsiano R, Soteli S, de Sanjosé S, Changalucha J, Kapiga S, Hayes RJ: Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study. PLoS One 2012, 7:1-10.
35. Hopkins TG, Wood N: Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 2013, 31:1673-1679.
36. Rothman AJ, Bartels RD, Wlaschin J, Salovey P: The strategic use of gain-and loss-framed messages for encouraging disease prevention behaviors: A meta-analytic review. J of Health Commun 2006, 12:623-644.
37. Hood JE, Friedman AL: Unveiling the hidden epidemic: a review of stigma associated with sexually transmissible infections. Sex Health 2011, 8:159-170.
38. Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, Welty T, Manga S, Ogembo JG: Awareness, acceptability and uptake of human papilloma virus vaccine among Cameroonian school-attending female adolescents. J Community Health 2012, 37:1127-1135.
39. Levin A, Wang SA, Levin C, Tsu V, Hutubessy R: Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLOS One In press.
40. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J: Assessment of eight HPV Vaccination programs implemented in lowest income countries. BMC Public Health 2012, 12:370.
41. Wakadha H, Chandir S, Were EV, Rubin A, Obor D, Levine OS, Gibson DG, Odhiambo F, Laserson KF, Feikin DR: The feasibility of using mobile-phone based SMS reminders and conditional cash transfers to improve timely immunization in rural Kenya. Vaccine 2013, 31:987-993.
42. WHO: Principles and considerations for adding a vaccine to a national immunization programme: From decision to implementation and monitoring. 2014, [http://apps.who.int/iris/bitstream/10665/111548/1/ 9789241506892-eng.pdf?ua=1]
43. GAVI Alliance: 206,000 more girls to benefit from HPV vaccine with GAVI Alliance support. 2014, [http://www.gavi.org/library/news/press-releases/ 2014/206-000-more-girls-to-benefit-from-hpv-vaccine-with-gavi-alliancesupport/]